FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 09/2022”.

The Monitor is a month-to-month printed overview of enterprise capital developments within the US-Biotech sector.

As of the tip of  September 2022, we establish the next present VC developments within the US-Biotech sector:

  • In 2022, general Biotech funding within the USA has reached USD 23,869m to this point
  • The highest 5 offers exceed USD 340m every, largest transaction amounted to USD 3,000m in Altos Labs
  • ARCH Enterprise Companions (USA) is main the High 5 Buyers (by deal quantity), adopted by 8VC (USA) and Alexandria Enterprise Investments (USA)
  • Oncology dominates as the highest indication

To entry the total report, please click on right here.

By Dr. Mathias Schott, Sebastian Sommer and Johannes Hyperlink

Leave a Reply

Your email address will not be published.